Targeting leukocyte migration and adhesion in Crohn's disease and ulcerative colitis

被引：191

作者：

Saskia Thomas

Daniel C. Baumgart

机构：

[1] Department of Medicine, University of Berlin, Virchow Hospital, Berlin

来源：

Inflammopharmacology | 2012年 / 20卷 / 1期

关键词：

Adhesion; Chemokines; Crohn's disease; Dendritic cells; IBD; Immunoglobulin superfamily cellular adhesion molecules; Inflammatory bowel disease; Integrins; Leukocytes; Migration; Recruitment; T-cells; Ulcerative colitis;

D O I：

10.1007/s10787-011-0104-6

中图分类号：

学科分类号：

摘要：

Crohn's disease and ulcerative colitis are two chronic inflammatory bowel diseases. Current biologic therapies are limited to blocking tumor necrosis factor alpha. However, some patients are primary non-responders, experience a loss of response, intolerance or side effects defining the urgent unmet need for novel treatments. The rapid recruitment and inappropriate retention of leukocytes is a hallmark of chronic inflammation and a potentially promising therapeutic target. We discuss the immunological mechanisms of leukocyte homing and adhesion in the gut mucosa. The interaction of lymphocytes (CD4 + T-cells, CD8 + T-cells, T REG, T H1, T H17, B-cells), monocytes, macrophages, dendritic cells and granulocytes with endothelial and epithelial cells through integrins [α4β7 (LPAM-1), α E7beta; 7 (HML1 Human Mucosal Lymphocyte Antigen 1), α 4β 1 (VLA-4), α Lβ 7, (LFA-1)] and their ligands immunoglobulin superfamily cellular adhesion molecules (CAM) (MAdCAM-1 Mucosal Addressin Cellular Adhesion Molecule 1, ICAM-1 Intercellular Cell Adhesion Molecule, VCAM-1 Vascular Cell Adhesion Molecule), fibronectin as well as chemokine receptors (CCR2, CCR4, CCR5, CCR7, CCR9, CCR10, CXCR3, CX3CR1) and chemokines [CCL5, CCL25 (TECK Thymus Expressed Chemokine), CCL28, CX3CL1, CXCL10, CXCL12] in the process of gut homing is critically reviewed and summarized in scientific cartoons. Moreover, we discuss the clinical trial results of approved and investigational antibodies and small molecules including natalizumab (anti-α 4, Tysabri®, Antegren®), AJM300 (anti-α4), etrolizumab (anti-β7, rhuMAb-Beta7), vedolizumab (anti-α4β7, LDP- 02, MLN-02, MLN0002), PF-00547659 (anti-MAdCAM), Alicaforsen (anti-ICAM-1), and CCX282-B (anti-CCR9, GSK-1605786, Traficet-EN™) and their risks such as PML reported for natalizumab. Hopefully, the newer gut specific drug designs discussed in this article will have an impact on both efficacy and safety. © Springer Basel AG 2011.

引用

页码：1 / 18

页数：17

共 135 条

[1]

Agace W.W., Tissue-tropic effector T cells: Generation and targeting opportunities, Nat Rev Immunol, 6, pp. 682-692, (2006)

[2]

Allez M., Vermeire S., Mozziconacci N., Michetti P., Laharie D., Louis E., Bigard M.A., Hebuterne X., Treton X., Kohn A., Marteau P., Cortot A., Nichita C., Van A.G., Rutgeerts P., Lemann M., Colombel J.F., The efficacy and safety of a third anti- TNF monoclonal antibody in Crohn's disease after failure of two other anti-TNF antibodies, Aliment Pharmacol Ther, 31, pp. 92-101, (2010)

[3]

Annacker O., Coombes J.L., Malmstrom V., Uhlig H.H., Bourne T., Johansson-Lindbom B., Agace W.W., Parker C.M., Powrie F., Essential role for CD103 in the T cell-mediated regulation of experimental colitis, J Exp Med, 202, pp. 1051-1061, (2005)

[4]

Aranda R., Sydora B.C., Mcallister P.L., Binder S.W., Yang H.Y., Targan S.R., Kronenberg M., Analysis of intestinal lymphocytes in mouse colitis mediated by transfer of CD4?, CD45RBhigh T cells to SCID recipients, J Immunol, 158, pp. 3464-3473, (1997)

[5]

Barczyk M., Carracedo S., Gullberg D., Integrins, Cell Tissue Res, 339, pp. 269-280, (2010)

[6]

Baumgart D.C., Carding S.R., Inflammatory bowel disease: Cause and immunobiology, Lancet, 369, pp. 1627-1640, (2007)

[7]

Baumgart D.C., Sandborn W.J., Inflammatory bowel disease: Clinical aspects and established and evolving therapies, Lancet, 369, pp. 1641-1657, (2007)

[8]

Bekker P., Velde A., Pronk I., Keshav S., Hommes D., Hanauer S., Ungashe S., Zheng W., Wright K., Schall T., Traficet-EN (CCX282-B), an orally active inhibitor of chemokine receptor CCR9, for treatment of Crohn's disease, Inflamm Bowel Dis, 13, (2007)

[9]

Bekker P., Petryka R., Vanasek T., Niv Y., Marlicz K., Haagen-Nielsen O., Dahelrup J., Dotan I., Compel V., Keshav S., Schall T.J., PROTECT-1, a prospective randomized oral therapy evaluation of CCX282-B (Traficet-EN) in Crohn's disease trial, Inflamm Bowel Dis, 14, 1, (2008)

[10]

Bekker P., Keshav S., Johnson D., Schall T.J., PROTECT-1 maintenance phase study results demonstrate efficacy of the intestine-specific chemokine receptor antagonist CCX282-B (Traficet-EN) in Crohn's disease, Inflamm Bowel Dis, 15, 12, (2009)

← 1 2 3 4 5 6 7 8 9 10 →